Inventor

NOELLE RANDOLPH J

US47 patents

⚠️ This page may combine multiple inventors who share the name “NOELLE RANDOLPH J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

NOELLE RANDOLPH J

DARTMOUTH COLLEGE

Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells

Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies

Regulatory T cell mediator proteins and uses thereof

Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties

Treatment of T cell mediated autoimmune disorders

Immunotherapy comprising TLR9 ligand and CD40 ligand

Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent

Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists

Method to treat multiple sclerosis with GP39-specific antibodies

Regulatory T cell mediator proteins and uses thereof

VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof

Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties

Immunostimulatory combinations

VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

Methods of immune therapy with anti-CD154 antibodies having Fc modifications

Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties

Methods for reducing T cell responsiveness to an autoantigen with anti-gp39 antibodies and antigen presenting cells

Vista antagonist and methods of use

Nucleic acids encoding an anti-CD154 antibody comprising E269R and K322A mutations

VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties and related therapies

Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties

Anti-CD40CR MR1 antibody

Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies

NOELLE RANDOLPH J

Vista regulatory T cell mediator protein, vista binding agents and use thereof

Regulatory T cell mediator proteins and uses thereof

Regulatory T cell mediator proteins and uses thereof

Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity

Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties

Regulatory T cell mediator proteins and uses thereof

Ex vivo uses of immunostimulatory combinations

Regulatory T cell mediator proteins and uses thereof

Compositions and methods for producing adaptive regulatory T cells

Method for modulating inflammatory responses

KING S COLLEGE LONDON

Vista modulators for diagnosis and treatment of cancer

Vista modulators for diagnosis and treatment of cancer

VISTA antagonist and methods of use

Vista antagonist and methods of use

3M INNOVATIVE PROPERTIES CO

Immunostimulatory combinations

TLR9 agonist and CD40 agonist immunostimulatory combinations

BRISTOL MYERS SQUIBB CO

Anti-GP39 antibodies

UNIV MASSACHUSETTS MEDICAL

Methods of inducing T cell unresponsiveness to donor tissue or organ in a recipient with GP39 antagonists

TRUSTEES OF DARTHMOUTH COLLEGE

Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1

GREEN KATHY A

Use of vista agonists and antagonists to suppress or enhance humoral immunity